In an immunohistochemical study, survivin over-expression was detected in surgically resected primary tumour specimens of breast cancers [158], and recent studies reported that survivin is linked to aggressive breast cancers [159], resistance to apoptosis [160] and modulation of HER-2 signalling [161]. Here, ERBB2 is linked to neoplasm.